Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism.
Jon R
JR
Nash
Sue J
SJ
Wilson
John P
JP
Potokar
David J
DJ
Nutt
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects; D003000:Clonidine / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008803:Mianserin / Q000009:adverse effects* / Q000031:analogs & derivatives*; D008875:Middle Aged; D000078785:Mirtazapine; D020734:Parkinsonian Disorders / Q000150:complications / Q000503:physiopathology*; D020187:REM Sleep Behavior Disorder / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy*; D012008:Recurrence; D016896:Treatment Outcome
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D008803:Mianserin; D000078785:Mirtazapine; D003000:Clonidine